CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes

详细信息	查看全文 | 推荐本文 |

• 作者：Bianca Mostert^a ; ^b ; ^{b.mostert@erasmusmc.nl} ; Jaco Kraan^a ; Anieta M. Sieuwerts^b ; Petra van der Spoel^a ; Joan Bolt-de Vries^b ; Wendy J.C. Prager-van der Smissen^b ; Marcel Smid^b ; Annemieke M. Timmermans^b ; John W.M. Martens^b ; Jan W. Gratama^a ; John A. Foekens^b ; Stefan Sleijfer^a ; ^b
• 关键词：Circulating tumor cells ; Breast cancer ; CellSearch ; Cytokeratin ; CD49f
• 刊名：Cancer Letters
• 出版年：2012
• 期刊代码：44_03043835
• 类别：med
• 出版时间：1 June, 2012
• 卷：319
• 期：1
• 页码：49-55
• 文件大小：660 K

摘要

Circulating tumor cells (CTCs) can be enumerated using CellSearch, but not all breast cancer subtypes, specifically those with epithelial-mesenchymal transition (EMT) characteristics, sufficiently express the enrichment (EpCAM) and selection (CK8/18/19) markers used in this method. While CD146 can detect EpCAM-negative CTCs, we here evaluated the value of various cytokeratins and CD49f to detect CK8/18/19-negative CTCs. The tested cytokeratins provided no substantial benefit, but adding CD49f to CK8/18/19 as a selection marker resulted in improved recovery of normal-like cell lines.

Combined staining of CK8/18/19 and CD49f after CD146/EpCAM enrichment is likely to further improve CTC detection in breast cancer.